What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?

Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2284
https://www.valueinhealthjournal.com/article/S1098-3015(14)04214-4/fulltext
Title : What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04214-4&doi=10.1016/j.jval.2014.08.2284
First page : A636
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 1742
Categories :
Tags :
Regions :
ViH Article Tags :